On November 3, 2016 Poseida Therapeutics Inc. ("Poseida"), a San Diego-based company translating best-in-class gene editing technologies into lifesaving therapeutics, reported that three abstracts detailing preclinical data on P-BCMA-101, the company’s BCMA-specific CAR-T drug candidate, have been selected for presentation at the American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting (Press release, Poseida Therapeutics, NOV 3, 2016, View Source [SID1234516624]). The studies explore utility and performance of Poseida’s proprietary CAR-T modifications using its piggyBac non-viral gene delivery system and Centyrin binding scaffold. Data will be presented at the 2016 ASH (Free ASH Whitepaper) Annual Meeting in San Diego on December 3rd and 5th. Abstracts are currently available online at View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The following abstracts will be presented:

Presentation Title: A Novel BCMA-Specific, Centyrin-Based CAR-T Product for the Treatment of Multiple Myeloma
Abstract Number: 2127
Date and Time: 5:30 p.m. – 7:30 p.m., Saturday, December 3, 2016
Location: San Diego Convention Center, Hall GH

Presentation Title: piggyBac-Produced CAR-T Cells Exhibit Stem-Cell Memory Phenotype
Abstract Number: 2167
Date and Time: 5:30 p.m. – 7:30 p.m., Saturday, December 3, 2016
Location: San Diego Convention Center, Hall GH

Presentation Title: Development of Novel Non-Immunoglobulin Centyrin-Based CARs (CARTyrins) Targeting Human BCMA
Abstract Number: 4557
Date and Time: 6:00 p.m. – 8:00 p.m., Monday, December 5, 2016
Location: San Diego Convention Center, Hall GH